Properties (68)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Cannabis research companies
|
| gptkbp:annualVisitors |
$10 million
|
| gptkbp:awards |
Best Innovation in Pharma 2020
|
| gptkbp:brand |
Growing in the industry
Expanding presence |
| gptkbp:brandAmbassadors |
Integrity and quality
Healthcare_professionals |
| gptkbp:businessModel |
B2B_and_B2C
|
| gptkbp:CEO |
gptkb:David_M._H._Hurst
|
| gptkbp:clinicalTrials |
Ongoing
Cannabis efficacy studies Positive results in trials |
| gptkbp:collaborations |
Universities for clinical trials
|
| gptkbp:communityEngagement |
Health awareness programs
|
| gptkbp:communityEvents |
Industry conferences
|
| gptkbp:communityImpact |
Health improvement initiatives
|
| gptkbp:communityPartnerships |
Key industry players
|
| gptkbp:communitySupport |
Local charities
|
| gptkbp:customerBase |
Diverse clientele
|
| gptkbp:customerFeedback |
Positive reviews
|
| gptkbp:employeeCount |
Over 100
|
| gptkbp:financialPerformance |
Steady growth
|
| gptkbp:financials |
Venture capitalists
|
| gptkbp:focus |
Medical cannabis
|
| gptkbp:founded |
1995
|
| gptkbp:futurePlans |
Expand product line
|
| gptkbp:goal |
Improve patient outcomes
|
| gptkbp:hasResearchInterest |
Consumer trends analysis
|
| gptkbp:headCoach |
gptkb:Dr._John_W._Smith
|
| gptkbp:headquarters |
gptkb:London,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
MGC Group
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:investmentFocus |
Private equity firms
Transparent communication Healthcare_sector |
| gptkbp:market |
Global
Competitive leader New cannabinoid products Europe_and_North_America |
| gptkbp:mission |
Develop innovative therapies
|
| gptkbp:partnerships |
Various research institutions
Joint ventures Healthcare_providers |
| gptkbp:patentCitation |
Multiple cannabinoid formulations
|
| gptkbp:productQuality |
High standards
|
| gptkbp:products |
Rigorous testing standards
New formulations Cannabis-based products Pharmacies and clinics |
| gptkbp:regulatoryCompliance |
International standards
TGA_in_Australia |
| gptkbp:research |
Government grants
|
| gptkbp:researchAreas |
Cannabinoid-based therapies
|
| gptkbp:researchInterest |
Peer-reviewed journals
International research teams Adherence to guidelines |
| gptkbp:services |
Research and development
|
| gptkbp:socialResponsibility |
Patient education programs
|
| gptkbp:stockSymbol |
gptkb:MXC
|
| gptkbp:strategicGoals |
Increase market share
|
| gptkbp:subsidiary |
MGC_Pharmaceuticals_Ltd.
|
| gptkbp:supplyChain |
Global suppliers
|
| gptkbp:sustainabilityInitiatives |
Eco-friendly_practices
|
| gptkbp:technology |
Advanced extraction methods
|
| gptkbp:training |
Continuous development programs
|
| gptkbp:vision |
Leader in cannabinoid research
|
| gptkbp:website |
www.mgcpharma.com
|